antibodies

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Auto-Antibody and Autoimmune Disease

Guest Editor:

Dr. Christiane Hampe
Department of Medicine, University of Washington, Seattle, Washington, WA 98109, USA

Deadline for manuscript submissions:
closed (30 November 2016)

Message from the Guest Editor

Dear Colleagues,

Autoantibodies in autoimmune disease can either present an epiphenomenon or can be active players in disease. While epiphenomenal autoantibodies are the result of an upstream event and have no clear effect on disease development, they can be useful to predict disease and as they reflect the underlying immune response. Pathogenic autoantibodies affect the disease pathway in a number of ways, including deposition of immune complexes and inflammation, stimulation and inhibition of receptor functions, stimulation and inhibition of enzyme functions, and facilitated antigen-uptake. This Special Issue of *Antibodies* focuses on disease-associated autoantibodies, with specific emphasis on different pathogenic mechanism, potential therapeutic options and critical information that can be derived from the study of autoantibodies.

Dr. Christiane Hampe
Guest Editor

antibodies

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 9.6

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra
Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: CiteScore - Q1 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
𝕏@Antibodies_MDPI